Baxter Healthcare Company

Farmaceutisch bedrijf3 producten gevolgd

producten gevolgd

197.972

totaal meldingen

recalls geregistreerd

96,3%

ernstig algeheel

Producten

3 van 3 getoond

Product	Goedgekeurd	Meldingen ↓	Top signaal	Recalls
cyclophosphamide injection, solution —	—	172.252	koortsige neutropenie	0
ifosfamide —	1987	20.887	Terugkerend diffuus grootcellig B-cellymfoom	3
mannitol —	1964	4.833	appendicoliet	31

Recall-geschiedenis · 24 geregistreerd

Datum	Klasse	Reden	Bedrijf
8 mrt 2022	II	Super Potent and Failed Reconstitution Time	Olympia Compounding Pharmacy dba Olympia Pharmacy
8 mrt 2022	II	Product found to be Sub Potent or Exceeded reconstitution time	Olympia Compounding Pharmacy dba Olympia Pharmacy
8 mrt 2022	III	Sub Potent	Olympia Compounding Pharmacy dba Olympia Pharmacy
8 mrt 2022	II	Sub Potent	Olympia Compounding Pharmacy dba Olympia Pharmacy
8 mrt 2022	III	Super Potent	Olympia Compounding Pharmacy dba Olympia Pharmacy
20 nov 2020	II	CGMP deviations: Lack of potency testing.	Complete Pharmacy and Medical Solutions, LLC.
20 nov 2020	II	CGMP deviations: Lack of potency testing.	Complete Pharmacy and Medical Solutions, LLC.
20 nov 2020	II	CGMP deviations: Lack of potency testing.	Complete Pharmacy and Medical Solutions, LLC.
20 nov 2020	II	CGMP deviations: Lack of potency testing.	Complete Pharmacy and Medical Solutions, LLC.
12 jun 2019	II	Lack of Assurance of Sterility	Infusion Options, Inc.
10 sep 2018	II	Lack of Assurance of Sterility	Pharm D Solutions, LLC
10 sep 2018	II	Lack of Assurance of Sterility	Pharm D Solutions, LLC
10 sep 2018	II	Lack of Assurance of Sterility	Pharm D Solutions, LLC
10 sep 2018	II	Lack of Assurance of Sterility	Pharm D Solutions, LLC
10 sep 2018	II	Lack of Assurance of Sterility	Pharm D Solutions, LLC
15 aug 2017	II	Lack of Assurance of Sterility.	Bella Pharmaceuticals, Inc.
8 mrt 2016	II	Chemical Contamination: Potential for contamination of the products with an aromatic hydrocarbon resin.	Hospira Inc.
2 jun 2015	II	Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility	The Compounding Pharmacy of America
27 aug 2014	II	Lack of Assurance of Sterility: Martin Avenue Pharmacy, Inc. is conducting a voluntary recall of all compounded sterile preparations within expiry. The recall is being initiated in connection with a recent FDA inspection due to observations associated with certain quality control procedures that present a risk to sterility assurance.	Martin Avenue Pharmacy, Inc.
27 aug 2014	II	Lack of Assurance of Sterility: Martin Avenue Pharmacy, Inc. is conducting a voluntary recall of all compounded sterile preparations within expiry. The recall is being initiated in connection with a recent FDA inspection due to observations associated with certain quality control procedures that present a risk to sterility assurance.	Martin Avenue Pharmacy, Inc.
12 mei 2014	II	Lack of Assurance of Sterility: Lack of sterility assurance in compounded aseptically filled injectable products.	John W Hollis Inc
13 sep 2013	II	Temperature abuse: Certain vials of Ifosfamide IV products were not refrigerated at certain Amerisource Bergen Drug Corp distribution centers.	AmeriSource Bergen
13 sep 2013	II	Temperature abuse: Certain vials of Ifosfamide IV products were not refrigerated at certain Amerisource Bergen Drug Corp distribution centers.	AmeriSource Bergen
28 mei 2013	II	The firm received seven reports of adverse reactions in the form of skin abscesses potentially linked to compounded preservative-free methylprednisolone 80mg/ml 10 ml vials.	Main Street Family Pharmacy, LLC

Class I = redelijke kans op ernstige schade · Class II = tijdelijk of omkeerbaar · Class III = onwaarschijnlijk schadelijk.

Registratiestatus

Sommige producten van Baxter Healthcare Company zijn niet FDA-geregistreerd voor humaan gebruik. Voor ongeregistreerde stoffen (peptiden, SARMs zonder humane registratie) bestaat geen legitieme leverancier voor humaan gebruik. Het ontbreken van een inkooproute is de veiligheidsinformatie.